NeuroSigma’s Monarch eTNS System Receives CE Mark Approval for ADHD

NeuroSigma®, Inc. (NeuroSigma) announced that it has received CE Mark approval for its Monarch eTNS System® as treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children age 7 and older.  This CE Mark approval is the first for any non-drug treatment of ADHD in the European Union (EU).

NeuroSigma is a California-based life sciences company focused on commercialization of its non-invasive eTNS technology for the treatment of neurological and neuropsychiatric disorders. With this approval, NeuroSigma's Monarch eTNS system is now available in the European Union for the treatment of ADHD and for the adjunctive . . .